A number of companies within Mubadala Capital’s ventures portfolio are taking crucial steps to support the response against the COVID-19 pandemic. Four companies are working on potential treatments to help fight the virus, which include VIR Biotechnology, Recursion Pharmaceuticals, Color Genomics and Innovaccer.
Ibrahim Ajami, Head of Ventures, emphasizes on how the combination of technology and biology will have a significant positive impact on healthcare challenges around the world.
VIR Biotechnology, a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is developing a vaccine against COVID-19 with plans to be in chemical trials by summer 2020, as researchers have identified two monoclonal antibodies (mAbs) that could work on the novel coronavirus. Additionally, the company has launched three key collaborations that should accelerate the pace of innovations needed to get to a therapy before the end of 2020: one with Wuxi Biologics in Shanghai, one with Biogen and one with Alnylam Pharma.
Recursion Pharmaceuticals, a company specialized in reengineering drug discovery through digital biology, is using Artificial Intelligence and Robotics to screen thousands of FDA-approved and ‘Generally Recognized as Safe’ compounds to determine efficacy against COVID-19. If the project is successful, the company will share any useful discoveries with relevant institutions and the biotech community, without seeking IP or profits, to enable the further development of treatments.
Color Genomics, best known for at-home genetic testing for disease risk genes, is launching a high-throughput, CLIA-certified COVID-19 testing laboratory integrated with public health tools. The testing facility, based in Burlingame, CA, will begin processing clinical samples to support public health efforts with a near-term goal of performing over 15,000 tests per day.
Innovaccer’s COVID-19 Management System for health systems, governments and health organizations provides digital framework for triaging, telemedicine, outreach and management to fight the pandemic. Five governments and 500 doctors in the US have used the system to screen and triage more than 150,000 citizens and patients.